- Home
- KTTA vs RSLS Comparison
KTTA vs RSLS Comparison
Compare KTTA & RSLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KTTA
- RSLS
- Stock Information
- Founded
- KTTA 2020
- RSLS 2002
- Country
- KTTA United States
- RSLS United States
- Employees
- KTTA N/A
- RSLS N/A
- Industry
- KTTA Biotechnology: Pharmaceutical Preparations
- RSLS Medical/Dental Instruments
- Sector
- KTTA Health Care
- RSLS Health Care
- Exchange
- KTTA Nasdaq
- RSLS Nasdaq
- Market Cap
- KTTA 5.5M
- RSLS 4.5M
- IPO Year
- KTTA 2021
- RSLS 2007
- Fundamental
- Price
- KTTA $0.68
- RSLS $2.39
- Analyst Decision
- KTTA
- RSLS Hold
- Analyst Count
- KTTA 0
- RSLS 1
- Target Price
- KTTA N/A
- RSLS N/A
- AVG Volume (30 Days)
- KTTA 142.8K
- RSLS 4.4M
- Earning Date
- KTTA 08-12-2025
- RSLS 08-13-2025
- Dividend Yield
- KTTA N/A
- RSLS N/A
- EPS Growth
- KTTA N/A
- RSLS N/A
- EPS
- KTTA N/A
- RSLS N/A
- Revenue
- KTTA N/A
- RSLS $7,175,000.00
- Revenue This Year
- KTTA N/A
- RSLS $52.80
- Revenue Next Year
- KTTA N/A
- RSLS N/A
- P/E Ratio
- KTTA N/A
- RSLS N/A
- Revenue Growth
- KTTA N/A
- RSLS N/A
- 52 Week Low
- KTTA $0.67
- RSLS $2.23
- 52 Week High
- KTTA $7.50
- RSLS $347.86
- Technical
- Relative Strength Index (RSI)
- KTTA 32.67
- RSLS 38.10
- Support Level
- KTTA $0.67
- RSLS $2.37
- Resistance Level
- KTTA $0.77
- RSLS $2.73
- Average True Range (ATR)
- KTTA 0.04
- RSLS 0.17
- MACD
- KTTA 0.01
- RSLS 0.21
- Stochastic Oscillator
- KTTA 14.02
- RSLS 13.33
About KTTA Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).
About RSLS ReShape Lifesciences Inc.
Reshape Lifesciences Inc is a medical device company focused on technologies to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus. Geographically, the company operates in the United States, Australia, Europe, and the Rest of world, and the majority of its revenue is generated from the United States.